메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

Epicsoft Asia Completes Compulsory Acquisition and Delisting of Ban Leong Technologies Limited

SINGAPORE, Aug. 25, 2025 -- Epicsoft Asia Pte. Ltd. ("Epicsoft Asia" or "Offeror"), an indirect subsidiary of GCL Global Holdings Ltd ("GCL") (NASDAQ: GCL), today announced it has completed the compulsory acquisition of Ban Leong Technologies Limited ("Ban Leong") on August 25, 2025, and that Ban Leong will be delisted from the Official List of the Singapore Exchange Securities Trading Limited ("SGX-ST") on August 26, 2025 (collectively, the "Announcement"). For over three decades, Ban Leong has been a le
- 황정호 기자
- 2025-08-25 17:30
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

SHANGHAI, Aug. 25, 2025 -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter
- 김갑성 기자
- 2025-08-25 16:42
CreatorWeek 2025 to Launch in Macao, Merging Eastern and Western Cultures Through 5-Day Business, Content, and Community Celebration

MACAO, Aug. 25, 2025 -- Macao Government Tourism Office (MGTO) and co-organizers, Branded, will host CreatorWeek Macao 2025 from October 24-28, 2025, focusing on the global creator economy, culture, entertainment, and community. The event aims to highlight Macao's vibrant creative economy and status as a hub for cultural exchange between East and West. Amid the rapid rise of the global creator economy and Macao's window of opportunity, CreatorWeek Macao will unite leading Chinese and Western social media platforms, top global content creators, and celebrity guests in an annual
- 김장윤(JASON KIM) 기자
- 2025-08-25 16:00
CreatorWeek 2025がマカオで開幕、5日間のビジネス、コンテンツ、コミュニティの祭典を通じて東洋と西洋の文化を融合

[ 메디채널 김장윤(JASON KIM) 기자 ] マカオ、2025年8月25日 -- Macao Government Tourism Office（MGTO）と共催者のBrandedは、2025年10月24日から28日までCreatorWeek Macao 2025を開催します。この催しは、グローバルなクリエイター経済、文化、エンターテインメント、コミュニティに焦点を当てた祭典です。このイベントは、マカオの活気あるクリエイティブな経済に光を当て、東洋と西洋の文化交流の拠点としての地位を際立たせることを目的としています。グローバルなクリエイター経済の急速な成長とマカオの機会窓を背景に、CreatorWeek Macaoは、中国と西欧の主要なソーシャル・メディア・プラットフォーム、世界トップクラスのコンテンツ・クリエイター、著名なゲストを毎年集め、創造性と文化の祭典を繰り広げています。中国と西欧の影響を橋渡しする都市であるマカオは、Douyin、RedNote、WeChatに加え、TikTok、Instagram、Facebook、YouTubeといった主要プラットフォームが自由に利用できる世界で唯一の場所です。このユニークな開放性により、マカオは中国語圏のユーザとグローバルなデジタル・コミュニティを結ぶ理想的なゲートウェイです。このイベント
- 김장윤(JASON KIM) 기자
- 2025-08-25 16:00
마카오서 열리는 '크리에이터위크 2025'…5일간 동서양 문화 아우르는 비즈니스•콘텐츠•커뮤니티 축제

[ 메디채널 김장윤(JASON KIM) 기자 ] 마카오 2025년 8월 25일 -- 마카오정부관광청(MGTO)과 공동 주최사 브랜디드(Branded)가 10월 24일부터 28일까지 '크리에이터위크 마카오 2025(CreatorWeek Macao 2025)'를 개최한다고 밝혔다. 이번 행사는 글로벌 크리에이터 경제, 문화, 엔터테인먼트, 커뮤니티를 조명하며, 마카오의 역동적인 창의 산업과 동서양 문화 교류 허브로서의 위상을 한층 부각할 예정이다. 글로벌 크리에이터 경제가 빠르게 성장하는 가운데 마카오는 기회의 장으로 부상하고 있다. 크리에이터위크 마카오는 중국과 서양의 주요 소셜 미디어 플랫폼, 세계적 콘텐츠 크리에이터, 유명 인사들이 함께하는 연례 창의•문화 축제로 개최된다. 중국과 서양 문화가 공존하는 도시 마카오는 전 세계에서 유일하게 틱톡, 인스타그램, 페이스북, 유튜브는 물론 더우인(Douyin), 레드노트(RedNote), 위챗(WeChat) 등 중국의 주요 플랫폼까지 이용할 수 있는 환경을 갖추고 있다. 이러한 독특한 개방성을 바탕으로 마카오는 중국어권 사용자와 글로벌 디지털 커뮤니티를 연결하는 이상적인 관문으로 자리
- 김장윤(JASON KIM) 기자
- 2025-08-25 16:00
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

[ 메디채널 김갑성 기자 ] The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 DEEs are the most severe rare epilepsies, characterized by drug-resistant seizures, frequent epileptic activity on EEG and developmental slowing or regression2 Bexicaserin, which has been granted Breakthrough Therapy designation by the FDA, demonstrated reductions in countable and total motor se
- 김갑성 기자
- 2025-08-25 15:43
Galan Lithium Limited: SUCCESSFUL DUE DILIGENCE COMPLETED - $20M PLACEMENT TO PROCEED

Highlights: All conditions in relation to the $20 million placement to Clean Elements Fund have been satisfied. Due diligence undertaken by Clean Elements Fund validates the standing of Hombre Muerto West (HMW) as a world class lithium project, offering exceptional scale and grade. Galan is now fully funded to complete the construction of Phase 1 at HMW (at 4ktpa LCE) with first production of lithium chloride concentrate planned during H1 2026. PERTH, Australia, Aug. 25, 2025 -- Galan Lithium Limited (ASX: GLN) (Galan or the Company) is pleased to announce that all cond
- 황정호 기자
- 2025-08-25 15:32
DAHON-V - a Revolutionary Bike Tech Pushing a New Frontier in Green Mobility

BEIJING, Aug. 25, 2025 -- At the "JD Cycling Festival" in Beijing, China, the silver-gray, drop-bar folding bike DAHON P18 Ultra zipped past the finish line and claimed victory with lightning speed, challenging the industry's perception that "portability and speed cannot coexist" for folding bikes. This decisive victory not only ignited a renewed interest in folding bikes among cycling enthusiasts but also brought DAHON's proprietary bike tech DAHON-V into the spotlight for its speed. DAHON-V Bike Tech: A revolutionary leap from the lab to track The s
- 황정호 기자
- 2025-08-25 15:07
Slow Travel Takes Hold in Bali with New Movenpick Bali Long-Stay Package

BALI, Indonesia, Aug. 25, 2025 -- It's late afternoon in Jimbaran and the pace feels unhurried. The sun drifts lower over the bay, fishermen haul in their nets, and visitors wander between market stalls or settle in for coffee at open-air cafés. This is a quieter side of Bali, one that rewards those who take their time. Travellers are beginning to embrace this slower rhythm, choosing longer stays and gentler itineraries instead of packing their days with back-to-back activities. It's less about ticking off the big-name sights and more about enjoying simple pleasures - a
- 김장윤(JASON KIM) 기자
- 2025-08-25 13:59
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints

HONG KONG, Aug. 25, 2025 -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study successfully met all primary efficacy endpoints, including ASAS20 and subgroup analyses, as well as the key secondary endpoint ASAS40. Furthermore, several pre-specified secondary endpoints demonstrated both statistically significant and clinically meaningful improvements, further supporting th
- 김갑성 기자
- 2025-08-25 13:46

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 06일 00시 40분